TerminatedNot applicableNCT03329404
Efficacy and Safety of RBCs Derived From Mirasol-treated Whole Blood in Patients Requiring Chronic Transfusion (PRAISE)
Studying Genetic hemoglobinopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Terumo BCTbio
- Principal Investigator
- Ned Cosgriff, MD, MD, MPHTerumo BCT
- Intervention
- Mirasol Red Blood Cells (MIR RBCs)(device)
- Enrollment
- 9 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2018 – 2018
Study locations (9)
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Weill-Cornell Medical College, New York, New York, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Rambam Health Care Campus, Haifa, Israel
- Hadassah Ein Kerem Hospital, Jerusalem, Israel
- Centro della Microcitemia ed Anemie Congenite Ospedale Gallieria, Genova, Genoa, Italy
- U.O.C. di Ematologia e Malattie Rare del Sangue e degli Organi Ematopoietici V. Cervello Hospital, Palermo, Italy
- Ege University Children's Hospital, Bornova, İzmir, Turkey (Türkiye)
Collaborators
United States Department of Defense · Joint Warfighter Medical Research Program · U.S. Army Medical Research and Development Command
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03329404 on ClinicalTrials.govOther trials for Genetic hemoglobinopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07087262A Phase I Study of SNH-119014 in Healthy VolunteersScinnoHub Pharmaceutical Co., Ltd.
- RECRUITINGNANCT06886477Sickle Cell, Pain and Mediterranean DietUniversity of Illinois at Chicago
- RECRUITINGPHASE1, PHASE2NCT06144749A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)Hillhurst Biopharmaceuticals, Inc.
- RECRUITINGNANCT07064941Effect of Exercise on Body Composition and Bone Health in Patients With ThalassemiaUniversity of California, San Francisco
- ACTIVE NOT RECRUITINGNANCT06800495Development of THALEA Kit and Its Impact on Knowledge, Attitude, and Intention for Premarital Thalassemia ScreeningUniversiti Teknologi Mara
- ENROLLING BY INVITATIONNCT07003256Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCTHaikou Affiliated Hospital of Central South University Xiangya School of Medicine
- RECRUITINGPHASE1, PHASE2NCT06481306A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseBristol-Myers Squibb
- RECRUITINGNANCT06031714Fetal Cell Receptors RepertoireAssistance Publique - Hôpitaux de Paris